Filtered By:
Specialty: Pharmaceuticals
Education: Study
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 397 results found since Jan 2013.
27.08.17: Not intended for U.S. and UK Media - Data from COMPASS study, including 27,395 patients, presented at ESC Congress 2017:
Bayer's Xarelto® significantly lowered the combined risk of stroke, cardiovascular death and heart attack in patients with chronic coronary or peripheral artery disease by 24%Importantly, rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100 mg once daily showed an unprecedented 42% relative risk reduction in stroke and 22% in cardiovascular death compared with aspirin 100 mg once daily alone / Bleeding rates were low, and while major bleeding was increased, notably there was no significant increase in intracranial or fatal bleeding / This combination regimen demonstrated a substantial improvement in net clinica...
Source: Bayer IR Newsfeed: Events - August 26, 2017 Category: Pharmaceuticals Source Type: news
Daily aspirin use may not prevent first heart attack
A daily aspirin did little to lower the probability of a stroke or heart attack in people who had not had a previous vascular event, new research shows.
The study, conducted by Brigham and Women's Hospital in Boston, gave aspirin or a placebo to 12,546 people who were thought to have a moderate risk of suffering a heart attack or stroke in the next 10 years, the Associated Press reported.
"Aspirin did not reduce the occurrence of major cardiova scular events in this study. However, there were…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 27, 2018 Category: Pharmaceuticals Authors: Anne Stych Source Type: news
Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals
The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately impacts the rate of stroke, compared to usual standard medical care.
Source: World Pharma News - November 15, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
ASA: Endocarditis, Related Strokes Up During Opioid Epidemic
WEDNESDAY, March 17, 2021 -- The incidence of infective endocarditis and resultant neurovascular complications has increased during the opioid epidemic, according to a study presented at the American Stroke Association International Stroke...
Source: Drugs.com - Pharma News - March 17, 2021 Category: Pharmaceuticals Source Type: news
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
ASA: Racial Differences Seen in Treatment of Common Poststroke Sequelae
MONDAY, Feb. 6, 2023 -- Considerable racial differences are seen in the treatment of common poststroke sequelae, according to a study presented at the American Stroke Association International Stroke Conference, held from Feb. 8 to 10 in...
Source: Drugs.com - Pharma News - February 6, 2023 Category: Pharmaceuticals Source Type: news
NeuroTrauma Sciences Commences First-in-Human Dosing in the US of Investigational Neuroprotective Drug NTS-104
Phase 1 safety study of NTS-104 is initiated in healthy volunteers
Compound is being developed for stroke and other Central Nervous System (CNS) injuries
ATLANTA, June 1, 2023 -- (Healthcare Sales & Marketing Network) -- NeuroTrauma Sciences, LLC (N... Biopharmaceuticals, Neurology, Drug Delivery NeuroTrauma Sciences, neurosteroid prodrug, stroke
Source: HSMN NewsFeed - June 1, 2023 Category: Pharmaceuticals Source Type: news
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news
Neurological Wellness Center Pays Tribute to Newly Released Study...
An observational study involving 629 subjects finds rapid, significant, readily-observable improvement in stroke and traumatic brain injury patients following the perispinal administration of Enbrel.(PRWeb January 02, 2013)Read the full story at http://www.prweb.com/releases/2013/1/prweb10268871.htm
Source: PRWeb: Medical Pharmaceuticals - January 2, 2013 Category: Pharmaceuticals Source Type: news
Atrial Fibrillation Linked To Increased Risk For Sudden Cardiac Death
Although atrial fibrillation (AF) is well known to be associated with an increase in the risk of stroke and coronary heart disease, a similar association with sudden cardiac death (SCD) has been suspected but not demonstrated in the past. Now a new study examing data from two large population studies offers evidence that AF is also an independent risk factor for SCD.
Source: Forbes.com Healthcare News - January 14, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
This Tasty Diet Can Prevent Heart Attacks And Strokes, Study Says
A large study conducted with funding from the Spanish government appears to have settled an old debate: What should people eat to avoid having a heart attack or stroke? It turns out it may not be how much fat you eat but what kind.
Source: Forbes.com Healthcare News - February 25, 2013 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
Study: Mediterranean Diet Benefits Heart
A diet with lots of olive oil and nuts cuts the risk of stroke and other major cardiovascular problems by 30% among high-risk people, according to a new study.
Source: WSJ.com: Health - February 25, 2013 Category: Pharmaceuticals Tags: FREE Source Type: news
Olive Oil Diet Curbs Strokes
A diet with lots of olive oil and nuts cuts the risk of stroke and other major cardiovascular problems by 30% among high-risk people, according to a new study.
Source: WSJ.com: Health - February 26, 2013 Category: Pharmaceuticals Tags: FREE Source Type: news
Boston Scientific Device Suffers Blow
Boston Scientific's experimental stroke-prevention device for patients with irregular heartbeats showed mixed results in a late-stage study, casting doubt on whether the device can gain regulatory approval in the U.S.
Source: WSJ.com: Health - March 11, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news
